Previous 10 | Next 10 |
Arrowhead Pharmaceuticals ( ARWR ) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhe...
CLEVELAND, Ohio, April 23, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem® cell therapy treatment of patients who...
Intro In this article, I will explain why I believe that Athersys ( ATHX ), a regenerative medicine company developing a mass-producible, allogeneic stem cell IV therapy for ischemic stroke, will succeed in its Phase 3 trial. And, even if potential competitors eventually secure FDA approva...
CLEVELAND, Ohio, April 15, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The event will focus on the Company’s mission, core capabilities and technologies, as well as progress made on develo...
CLEVELAND, April 10, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con...
The following slide deck was published by Athersys, Inc. in conjunction with this Read more ...
CLEVELAND, April 01, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the Company’s participation in two upcoming biotechnology and healthcare conferences. On April 4 th , Athersys will be part of the William Blair 3 rd Annual Late-Stage Therapeutics Conference...
Athersys, Inc. (ATHX) Q4 2018 Results Earnings Conference Call March 14, 2019, 04:30 PM ET Company Participants Laura Campbell - Senior Vice President, Finance Gil Van Bokkelen - Chairman and Chief Executive Officer BJ Lehmann - President and Chief Operating Officer Conference...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...